Publications in collaboration with researchers from Clínica Universitaria de Navarra (17)

2026

  1. HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study

    eClinicalMedicine, Vol. 91

  2. Haemostatic changes during CART cell therapy and risk of complications

    Cancer Immunology, Immunotherapy, Vol. 75, Núm. 4

2025

  1. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

    Blood Cancer Journal, Vol. 15, Núm. 1

  2. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study

    Transplant Infectious Disease, Vol. 27, Núm. 5

  3. Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC

    Frontiers in Immunology, Vol. 16

  4. Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

    Open Forum Infectious Diseases, Vol. 12, Núm. 11

  5. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care

    Frontiers in Immunology, Vol. 15

  6. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study

    British Journal of Haematology, Vol. 207, Núm. 4, pp. 1504-1516

  7. Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT

    Bone Marrow Transplantation

  8. Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

    Cancer Immunology, Immunotherapy, Vol. 74, Núm. 6

  9. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

    Cancers, Vol. 17, Núm. 19

  10. The role of stem cell transplantation in the modern management of multiple myeloma

    Current Opinion in Hematology

2024

  1. Cardiac events after allo-HCT in patients with acute myeloid leukemia

    Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509

  2. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703

  3. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

    Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973

2023

  1. Disseminated lymphadenopathy during chemotherapy for squamous cell lung carcinoma

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 7, pp. 438-440

2022

  1. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 703.e1-703.e8